This early-stage trial tests a single injection of ABI-110 gene therapy into the eye for people with wet age-related macular degeneration (AMD), a leading cause of vision loss. The goal is to see if it is safe and can reduce the need for frequent anti-VEGF injections by helping t…
Phase: PHASE1, PHASE2 • Sponsor: Avirmax Biopharma Inc • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC